CD19 and fungal infectious disease: reported a 3% incidence of fungal infections between days 0 and 28 amongst 133 patients who all received fluconazole prophylaxis during the period of neutropenia after CD19-directed CAR T-cell therapy; all patients with fungal infections were reported to have been treated for CRS or ICANS with tocilizumab and/or corticosteroids (11).